表紙:デング熱ワクチン市場:業界分析・市場規模・シェア・成長・動向・予測(2021年~2031年)
市場調査レポート
商品コード
1008606

デング熱ワクチン市場:業界分析・市場規模・シェア・成長・動向・予測(2021年~2031年)

Dengue Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

出版日: | 発行: Transparency Market Research | ページ情報: 英文 200 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.81円
デング熱ワクチン市場:業界分析・市場規模・シェア・成長・動向・予測(2021年~2031年)
出版日: 2021年04月26日
発行: Transparency Market Research
ページ情報: 英文 200 Pages
納期: 即日から翌営業日
  • 概要
  • 図表一覧
  • 概要
  • 目次
概要

当レポートでは、世界のデング熱ワクチン市場を調査し、市場の概要、カテゴリー・製品・投与経路・地域・主要国別の成長率および市場規模の推移と予測、市場の成長要因および抑制要因の分析、市場機会、パイプライン分析、新型コロナウイルス感染症(COVID-19)の影響分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 序文

第2章 仮定と調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

  • イントロダクション
    • カテゴリー定義
    • 業界の発展動向
  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
  • 市場分析と予測(実績値・予測値)

第5章 重要洞察

  • パイプライン分析
  • 疾患有病率
  • 患者数
  • 新型コロナウイルス感染症(COVID-19)の短期・中期・長期的影響

第6章 世界のデング熱ワクチン市場の分析と予測:カテゴリー別

  • イントロダクション・定義
  • 主な調査結果・開発動向
  • 市場規模:製品別(実績値・予測値)
    • 弱毒生ワクチン
    • キメラ生弱毒化ワクチン
    • その他
  • 市場魅力分析:カテゴリー別

第7章 世界のデング熱ワクチン市場の分析と予測:製品別

  • イントロダクション・定義
  • 主な調査結果・開発動向
  • 市場規模:製品別(実績値・予測値)
    • CYD-TDV(デングワクチン)
    • その他
  • 市場魅力分析:製品別

第8章 世界のデング熱ワクチン市場の分析と予測:投与経路別

  • イントロダクション・定義
  • 主な調査結果・開発動向
  • 市場規模:投与経路別(実績値・予測値)
    • 皮下
    • その他
  • 市場魅力分析:投与経路別

第9章 世界のデング熱ワクチン市場の分析と予測:エンドユーザー別

  • イントロダクション・定義
  • 主な調査結果・開発動向
  • 市場規模:エンドユーザー別(実績値・予測値)
    • 病院
    • 政府機関
    • 専門クリニック
    • その他
  • 市場魅力分析:エンドユーザー別

第10章 世界のデング熱ワクチン市場の分析と予測:地域別

  • 主な調査結果
  • 市場規模:地域別(予測値)
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力分析:国・地域別

第11章 北米のデング熱ワクチン市場の分析と予測

  • イントロダクション
    • 主な調査結果
  • 市場規模:カテゴリー別(実績値・予測値)
    • 弱毒生ワクチン
    • キメラ生弱毒化ワクチン
    • その他
  • 市場規模:製品別(実績値・予測値)
    • CYD-TDV(デングワクシア/Dengvaxia)
    • その他
  • 市場規模:投与経路別(実績値・予測値)
    • 皮下
    • その他
  • 市場規模:エンドユーザー別(実績値・予測値)
    • 病院
    • 政府機関
    • 専門クリニック
    • その他
  • 市場規模:国別(実績値・予測値)
    • 米国
    • カナダ
  • 市場魅力分析
    • カテゴリー別
    • 製品別
    • 投与経路別
    • エンドユーザー別
    • 国別

第12章 欧州のデング熱ワクチン市場の分析と予測

第13章 アジア太平洋地域のデング熱ワクチン市場の分析と予測

第14章 ラテンアメリカのデング熱ワクチン市場の分析と予測

第15章 中東・アフリカのデング熱ワクチン市場の分析と予測

第16章 競合情勢

  • 市場シェア分析:企業別(2020年)
  • 企業プロファイル
    • Sanofi Pasteur Limited
    • Takeda Pharmaceutical Company Limited
    • Merck Co. &Inc.
    • GlaxoSmithKline plc
    • GeneOne Life Science
    • Medigen Vaccine Biologics
    • Panacea Biotec Limited
    • Sun Pharmaceutical Industries Ltd.
    • Serum Institute of India Pvt. Ltd.
    • Biological E
    • VabioTech
図表一覧(英語)

List of Tables

  • Table 01: Global Dengue Vaccines Market Value (US$ Mn) Forecast, by Category, 2017-2031
  • Table 02: Global Dengue Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 03: Global Dengue Vaccines Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 04: Global Dengue Vaccines Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Dengue Vaccines Market Value (US$ Mn) Forecast, by Sub-region, 2017-2031
  • Table 06: North America Dengue Vaccines Market Value (US$ Mn) Forecast, by Category, 2017-2031
  • Table 07: North America Dengue Vaccines Market Value (US$ Mn) Forecast, by Product, 2017-2031
  • Table 8: North America Dengue Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 09: North America Dengue Vaccines Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 10: Europe Dengue Vaccines Market Value (US$ Mn) Forecast, by Sub-region, 2017-2031
  • Table 11: Europe Dengue Vaccines Market Value (US$ Mn) Forecast, by Category, 2017-2031
  • Table 12: Europe Dengue Vaccines Market Value (US$ Mn) Forecast, by Product, 2017-2031
  • Table 13: Europe Dengue Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 14: Europe Dengue Vaccines Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 15: Asia Pacific Dengue Vaccines Market Value (US$ Mn) Forecast, by Sub-region, 2017-2031
  • Table 16: Asia Pacific Dengue Vaccines Market Value (US$ Mn) Forecast, by Category, 2017-2031
  • Table 17: Asia Pacific Dengue Vaccines Market Value (US$ Mn) Forecast, by Product, 2017-2031
  • Table 18: Asia Pacific Dengue Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 19: Asia Pacific Dengue Vaccines Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 20: Latin America Dengue Vaccines Market Value (US$ Mn) Forecast, by Sub-region, 2017-2031
  • Table 21: Latin America Dengue Vaccines Market Value (US$ Mn) Forecast, by Product, 2017-2031
  • Table 22: Latin America Dengue Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 23: Latin America Dengue Vaccines Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 24: Middle East & Africa Dengue Vaccines Market Value (US$ Mn) Forecast, by Sub-region, 2017-2031
  • Table 25: Middle East & Africa Dengue Vaccines Market Value (US$ Mn) Forecast, by Category, 2017-2031
  • Table 26: Middle East & Africa Dengue Vaccines Market Value (US$ Mn) Forecast, by Product, 2017-2031
  • Table 27: Middle East & Africa Dengue Vaccines Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 28: Middle East & Africa Dengue Vaccines Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Dengue Vaccines Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Dengue Vaccines Market Value Share, by Category, 2020
  • Figure 03: Global Dengue Vaccines Market Value Share, by Product, 2020
  • Figure 04: Global Dengue Vaccines Market Value Share, by End-user, 2020
  • Figure 05: Global Dengue Vaccines Market Value Share, by Region, 2020
  • Figure 06: Global Dengue Vaccines Market Value Share, by Route of Administration, 2020
  • Figure 07: Global Dengue Vaccines Market Value Share Analysis, by Category, 2020 and 2031
  • Figure 08: Global Dengue Vaccines Market Attractiveness Analysis, by Category, 2021-2031
  • Figure 09: Global Dengue Vaccines Market Value (US$ Mn), by Live Attenuated Vaccines Category, 2017-2031
  • Figure 10: Global Dengue Vaccines Market Value (US$ Mn), by Chimeric Live Attenuated Vaccines Category, 2017-2031
  • Figure 11: Global Dengue Vaccines Market Value (US$ Mn), by Others Category, 2017-2031
  • Figure 12: Global Dengue Vaccines Market Value Share Analysis, by Route of Administration, 2020 and 2031
  • Figure 13: Global Dengue Vaccines Market Attractiveness Analysis, by Route of Administration, 2021-2031
  • Figure 14: Global Dengue Vaccines Market Value (US$ Mn), by Subcutaneous, 2017-2031
  • Figure 15: Global Dengue Vaccines Market Value (US$ Mn), by Others, 2017-2031
  • Figure 16: Global Dengue Vaccines Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 17: Global Dengue Vaccines Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 18: Global Dengue Vaccines Market Value (US$ Mn), by Hospitals, 2017-2031
  • Figure 19: Global Dengue Vaccines Market Value (US$ Mn), by Government institutes, 2017-2031
  • Figure 20: Global Dengue Vaccines Market Value (US$ Mn), by Specialty Clinics, 2017-2031
  • Figure 21: Global Dengue Vaccines Market Value (US$ Mn), by Others, 2017-2031
  • Figure 22: Global Dengue Vaccines Market Value Share Analysis, by Region, 2020 and 2031
  • Figure 23: Global Dengue Vaccines Market Attractiveness Analysis, by Region, 2021-2031
  • Figure 24: North America Dengue Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 25: North America Dengue Vaccines Market Value Share, by Sub-region, 2020-2031
  • Figure 26: North America Dengue Vaccines Market Attractiveness Analysis, by Sub-region, 2021-2031
  • Figure 27: North America Dengue Vaccines Market Value Share Analysis, by Category, 2020 and 2031
  • Figure 28: North America Dengue Vaccines Market Attractiveness Analysis, by Category, 2021-2031
  • Figure 29: North America Dengue Vaccines Market Value Share Analysis, by Product, 2020 and 2031
  • Figure 30: North America Dengue Vaccines Market Attractiveness Analysis, by Product, 2021-2031
  • Figure 31: North America Dengue Vaccines Market Value Share Analysis, by Route of Administration, 2020 and 2031
  • Figure 32: North America Dengue Vaccines Market Attractiveness Analysis, by Route of Administration, 2021-2031
  • Figure 33: North America Dengue Vaccines Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 34: North America Dengue Vaccines Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 35: Europe Dengue Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 36: Europe Dengue Vaccines Market Value Share, by Sub-region, 2020-2031
  • Figure 37: Europe Dengue Vaccines Market Attractiveness Analysis, by Sub-region, 2021-2031
  • Figure 38: Europe Dengue Vaccines Market Value Share Analysis, by Category, 2020 and 2031
  • Figure 39: Europe Dengue Vaccines Market Attractiveness Analysis, by Category, 2021-2031
  • Figure 40: Europe Dengue Vaccines Market Value Share Analysis, by Product, 2020 and 2031
  • Figure 41: Europe Dengue Vaccines Market Attractiveness Analysis, by Product, 2021-2031
  • Figure 42: Europe Dengue Vaccines Market Value Share Analysis, by Route of Administration, 2020 and 2031
  • Figure 43: Europe Dengue Vaccines Market Attractiveness Analysis, by Route of Administration, 2021-2031
  • Figure 44: Europe Dengue Vaccines Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 45: Europe Dengue Vaccines Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 46: Asia Pacific Dengue Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 47: Asia Pacific Dengue Vaccines Market Value Share, by Sub-region, 2020-2031
  • Figure 48: Asia Pacific Dengue Vaccines Market Attractiveness Analysis, by Sub-region, 2021-2031
  • Figure 49: Asia Pacific Dengue Vaccines Market Value Share Analysis, by Category, 2020 and 2031
  • Figure 50: Asia Pacific Dengue Vaccines Market Attractiveness Analysis, by Category, 2021-2031
  • Figure 51: Asia Pacific Dengue Vaccines Market Value Share Analysis, by Product, 2020 and 2031
  • Figure 52: Asia Pacific Dengue Vaccines Market Attractiveness Analysis, by Product, 2021-2031
  • Figure 53: Asia Pacific Dengue Vaccines Market Value Share Analysis, by Route of Administration, 2020 and 2031
  • Figure 54: Asia Pacific Dengue Vaccines Market Attractiveness Analysis, by Route of Administration, 2021-2031
  • Figure 55: Asia Pacific Dengue Vaccines Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 56: Asia Pacific Dengue Vaccines Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 57: Latin America Dengue Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 58: Latin America Dengue Vaccines Market Value Share, by Sub-region, 2020-2031
  • Figure 59: Latin America Dengue Vaccines Market Attractiveness Analysis, by Sub-region, 2021-2031
  • Figure 60: Latin America Dengue Vaccines Market Value Share Analysis, by Category, 2020 and 2031
  • Figure 61: Latin America Dengue Vaccines Market Attractiveness Analysis, by Category, 2021-2031
  • Figure 62: Latin America Dengue Vaccines Market Value Share Analysis, by Product, 2020 and 2031
  • Figure 63: Latin America Dengue Vaccines Market Attractiveness Analysis, by Product, 2021-2031
  • Figure 64: Latin America Dengue Vaccines Market Value Share Analysis, by Route of Administration, 2020 and 2031
  • Figure 65: Latin America Dengue Vaccines Market Attractiveness Analysis, by Route of Administration, 2021-2031
  • Figure 66: Latin America Dengue Vaccines Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 67: Latin America Dengue Vaccines Market Attractiveness Analysis, by End-user, 2021-2031
  • Figure 68: Middle East & Africa Dengue Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
  • Figure 69: Middle East & Africa Dengue Vaccines Market Value Share, by Sub-region, 2020-2031
  • Figure 70: Middle East & Africa Dengue Vaccines Market Attractiveness Analysis, by Sub-region, 2021-2031
  • Figure 71: Middle East & Africa Dengue Vaccines Market Value Share Analysis, by Category, 2020 and 2031
  • Figure 72: Middle East & Africa Dengue Vaccines Market Attractiveness Analysis, by Category, 2021-2031
  • Figure 73: Middle East & Africa Dengue Vaccines Market Value Share Analysis, by Product, 2020 and 2031
  • Figure 74: Middle East & Africa Dengue Vaccines Market Attractiveness Analysis, by Product, 2021-2031
  • Figure 75: Middle East & Africa Dengue Vaccines Market Value Share Analysis, by Route of Administration, 2020 and 2031
  • Figure 76: Middle East & Africa Dengue Vaccines Market Attractiveness Analysis, by Route of Administration, 2021-2031
  • Figure 77: Middle East & Africa Dengue Vaccines Market Value Share Analysis, by End-user, 2020 and 2031
  • Figure 78: Middle East & Africa Dengue Vaccines Market Attractiveness Analysis, by End-user, 2021-2031
概要(英語)
Product Code: TMRGL28397

Scope of the Report

TMR's report on the global dengue vaccines market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides revenue of the global dengue vaccines market for the period of 2017-2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global dengue vaccines market from 2021 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the dengue vaccines market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the dengue vaccines market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global dengue vaccines market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global dengue vaccines market.

The report delves into the competitive landscape of the global dengue vaccines market. Key players operating in the global dengue vaccines market are identified and each one of these is profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global dengue vaccines market profiled in this report.

Key Questions Answered:

  • What is the sales/revenue generated by dengue vaccines across all regions during the forecast period?
  • What are the opportunities in the global dengue vaccines market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which category is expected to generate the highest revenue globally in 2031? Which product is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Research Objectives and Research Approach

The comprehensive report on the global dengue vaccines market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global dengue vaccines market in terms of category, product, route of administration, end user, and region. Key segments under each criteria are studied at length, and the market share for each of these at the end of 2031 has also been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global dengue vaccines market.

目次(英語)

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Dengue Vaccines Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Category Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Dengue Vaccines Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Disease Prevalence
  • 5.3. Patient Volume
  • 5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Dengue Vaccines Market Analysis and Forecast, by Category

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Category, 2017-2031
    • 6.3.1. Live Attenuated Vaccines
    • 6.3.2. Chimeric Live Attenuated Vaccines
    • 6.3.3. Others
  • 6.4. Market Attractiveness Analysis, by Category

7. Global Dengue Vaccines Market Analysis and Forecasts, by Product

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Product, 2017-2031
    • 7.3.1. CYD-TDV (Dengvaxia)
    • 7.3.2. Others
  • 7.4. Market Attractiveness Analysis, by Product

8. Global Dengue Vaccines Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 8.3.1. Subcutaneous
    • 8.3.2. Others
  • 8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Dengue Vaccines Market Analysis and Forecast, by End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast, by End-user, 2017-2031
    • 9.3.1. Hospitals
    • 9.3.2. Government Institutes
    • 9.3.3. Specialty Clinics
    • 9.3.4. Others
  • 9.4. Market Attractiveness Analysis, by End-user

10. Global Dengue Vaccines Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast By Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness Analysis, by Country/Region

11. North America Global Dengue Vaccines Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Category, 2017-2031
    • 11.2.1. Live Attenuated Vaccines
    • 11.2.2. Chimeric Live Attenuated Vaccines
    • 11.2.3. Others
  • 11.3. Market Value Forecast, by Product, 2017-2031
    • 11.3.1. CYD-TDV (Dengvaxia)
    • 11.3.2. Others
  • 11.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.4.1. Subcutaneous
    • 11.4.2. Others
  • 11.5. Market Value Forecast, by End-user, 2017-2031
    • 11.5.1. Hospitals
    • 11.5.2. Government Institutes
    • 11.5.3. Specialty Clinics
    • 11.5.4. Others
  • 11.6. Market Value Forecast, by Country, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Category
    • 11.7.2. By Product
    • 11.7.3. By Route of Administration
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Europe Global Dengue Vaccines Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Category, 2017-2031
    • 12.2.1. Live Attenuated Vaccines
    • 12.2.2. Chimeric Live Attenuated Vaccines
    • 12.2.3. Others
  • 12.3. Market Value Forecast, by Product, 2017-2031
    • 12.3.1. CYD-TDV (Dengvaxia)
    • 12.3.2. Others
  • 12.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.4.1. Subcutaneous
    • 12.4.2. Others
  • 12.5. Market Value Forecast, by End-user, 2017-2031
    • 12.5.1. Hospitals
    • 12.5.2. Government Institutes
    • 12.5.3. Specialty Clinics
    • 12.5.4. Others
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Category
    • 12.7.2. By Product
    • 12.7.3. By Route of Administration
    • 12.7.4. By End-user
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Global Dengue Vaccines Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Category, 2017-2031
    • 13.2.1. Live Attenuated Vaccines
    • 13.2.2. Chimeric Live Attenuated Vaccines
    • 13.2.3. Others
  • 13.3. Market Value Forecast, by Product, 2017-2031
    • 13.3.1. CYD-TDV (Dengvaxia)
    • 13.3.2. Others
  • 13.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.4.1. Subcutaneous
    • 13.4.2. Others
  • 13.5. Market Value Forecast, by End-user, 2017-2031
    • 13.5.1. Hospitals
    • 13.5.2. Government Institutes
    • 13.5.3. Specialty Clinics
    • 13.5.4. Others
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Category
    • 13.7.2. By Product
    • 13.7.3. By Route of Administration
    • 13.7.4. By End-user
    • 13.7.5. By Country/Sub-region

14. Latin America Global Dengue Vaccines Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Category, 2017-2031
    • 14.2.1. Live Attenuated Vaccines
    • 14.2.2. Chimeric Live Attenuated Vaccines
    • 14.2.3. Others
  • 14.3. Market Value Forecast, by Product, 2017-2031
    • 14.3.1. CYD-TDV (Dengvaxia)
    • 14.3.2. Others
  • 14.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.4.1. Subcutaneous
    • 14.4.2. Others
  • 14.5. Market Value Forecast, by End-user, 2017-2031
    • 14.5.1. Hospitals
    • 14.5.2. Government Institutes
    • 14.5.3. Specialty Clinics
    • 14.5.4. Others
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Category
    • 14.7.2. By Product
    • 14.7.3. By Route of Administration
    • 14.7.4. By End-user
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Global Dengue Vaccines Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Category, 2017-2031
    • 15.2.1. Live Attenuated Vaccines
    • 15.2.2. Chimeric Live Attenuated Vaccines
    • 15.2.3. Others
  • 15.3. Market Value Forecast, by Product, 2017-2031
    • 15.3.1. CYD-TDV (Dengvaxia)
    • 15.3.2. Others
  • 15.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 15.4.1. Subcutaneous
    • 15.4.2. Others
  • 15.5. Market Value Forecast, by End-user, 2017-2031
    • 15.5.1. Hospitals
    • 15.5.2. Government Institutes
    • 15.5.3. Specialty Clinics
    • 15.5.4. Others
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Category
    • 15.7.2. By Product
    • 15.7.3. By Route of Administration
    • 15.7.4. By End-user
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Share Analysis, by Company, 2020
  • 16.2. Company Profiles
    • 16.2.1. Sanofi Pasteur Limited
      • 16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.1.2. Product Portfolio
      • 16.2.1.3. SWOT Analysis
      • 16.2.1.4. Strategic Overview
    • 16.2.2. Takeda Pharmaceutical Company Limited
      • 16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.2.2. Product Portfolio
      • 16.2.2.3. SWOT Analysis
      • 16.2.2.4. Strategic Overview
    • 16.2.3. Merck Co. & Inc.
      • 16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.3.2. Product Portfolio
      • 16.2.3.3. SWOT Analysis
      • 16.2.3.4. Strategic Overview
    • 16.2.4. GlaxoSmithKline plc
      • 16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.4.2. Product Portfolio
      • 16.2.4.3. SWOT Analysis
      • 16.2.4.4. Strategic Overview
    • 16.2.5. GeneOne Life Science
      • 16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.5.2. Product Portfolio
      • 16.2.5.3. SWOT Analysis
      • 16.2.5.4. Strategic Overview
    • 16.2.6. Medigen Vaccine Biologics
      • 16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.6.2. Product Portfolio
      • 16.2.6.3. SWOT Analysis
      • 16.2.6.4. Strategic Overview
    • 16.2.7. Panacea Biotec Limited
      • 16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.7.2. Product Portfolio
      • 16.2.7.3. SWOT Analysis
      • 16.2.7.4. Strategic Overview
    • 16.2.8. Sun Pharmaceutical Industries Ltd.
      • 16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.8.2. Product Portfolio
      • 16.2.8.3. SWOT Analysis
      • 16.2.8.4. Strategic Overview
    • 16.2.9. Serum Institute of India Pvt. Ltd.
      • 16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.9.2. Product Portfolio
      • 16.2.9.3. SWOT Analysis
      • 16.2.9.4. Strategic Overview
    • 16.2.10. Biological E
      • 16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.10.2. Product Portfolio
      • 16.2.10.3. SWOT Analysis
      • 16.2.10.4. Strategic Overview
    • 16.2.11. VabioTech
      • 16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.2.11.2. Product Portfolio
      • 16.2.11.3. SWOT Analysis
      • 16.2.11.4. Strategic Overview